Performance of CRSP Crispr Therapeutics AG | 5.2% in 12m
Compare CRSP with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Crispr Therapeutics AG with its related Sector/Index XBI
Performance Duell CRSP vs XBI
| TimeFrame | CRSP | XBI |
|---|---|---|
| 1 Day | 1.49% | 1.86% |
| 1 Week | 3.67% | 7.77% |
| 1 Month | -14.1% | 0.55% |
| 3 Months | -13.4% | 1.78% |
| 6 Months | 9.61% | 25.94% |
| 12 Months | 5.21% | 7.17% |
| YTD | -15.4% | -0.28% |
| Rel. Perf. 1m | -1.48 | |
| Rel. Perf. 3m | -1.88 | |
| Rel. Perf. 6m | 0.03 | |
| Rel. Perf. 12m | 0.12 |
Is Crispr Therapeutics AG a good stock to buy?
No, based on ValueRay Fundamental Analyses, Crispr Therapeutics AG (NASDAQ:CRSP) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -61.11 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRSP as of May 2024 is 49.64. This means that CRSP is currently overvalued and has a potential downside of -11.18% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRSP as of May 2024 is 49.64. This means that CRSP is currently overvalued and has a potential downside of -11.18% (Sold with Premium).
Is CRSP a buy, sell or hold?
- Strong Buy: 10
- Buy: 5
- Hold: 11
- Sell: 1
- Strong Sell: 2
Values above 0%: CRSP is performing better - Values below 0%: CRSP is underperforming
Compare CRSP with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 3.07% | -13.74% | -8.86% | -22.82% |
| US NASDAQ 100 | QQQ | 2.63% | -14.12% | -9.28% | -33.45% |
| US Dow Jones Industrial 30 | DIA | 2.50% | -14.34% | -5.01% | -13.78% |
| German DAX 40 | DBXD | 4.56% | -11.80% | -8.66% | -8.65% |
| UK FTSE 100 | ISFU | 2.01% | -16.43% | -4.76% | -5.14% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 0.16% | -17.64% | 6.40% | 15.98% |
| Hongkong Hang Seng | HSI | -2.09% | -22.91% | 10.81% | 19.79% |
| Japan Nikkei 225 | EXX7 | 1.32% | -9.73% | -4.01% | -14.17% |
| India NIFTY 50 | INDA | 2.89% | -16.34% | -9.82% | -22.83% |
| Brasil Bovespa | EWZ | 1.23% | -14.78% | 4.73% | -18.69% |
CRSP Crispr Therapeutics AG vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 3.55% | -12.28% | -9.73% | -35.32% |
| Consumer Discretionary | XLY | 2.53% | -14.12% | -1.87% | -19.07% |
| Consumer Staples | XLP | 3.29% | -16.34% | -2.42% | 3.08% |
| Energy | XLE | 6.98% | -9.48% | 0.92% | -17.40% |
| Financial | XLF | 4.33% | -12.56% | -11.48% | -25.61% |
| Health Care | XLV | 3.05% | -13.30% | -1.82% | -2.90% |
| Industrial | XLI | 3.58% | -13.14% | -12.26% | -22.13% |
| Materials | XLB | 3.66% | -11.47% | -5.23% | -11.42% |
| Real Estate | XLRE | 2.13% | -11.18% | 2.32% | 1.22% |
| Technology | XLK | 2.31% | -13.33% | -8.77% | -33.19% |
| Utilities | XLU | 0.32% | -19.38% | -2.94% | 2.04% |
| Aerospace & Defense | XAR | 1.19% | -15.87% | -5.96% | -20.34% |
| Biotech | XBI | -4.10% | -14.64% | -16.33% | -1.96% |
| Homebuilder | XHB | 2.22% | -12.34% | -26.73% | -47.28% |
| Retail | XRT | 3.40% | -12.72% | -9.44% | -20.14% |
Does Crispr Therapeutics AG outperform its market, is CRSP a Sector Leader?
No, over the last 12 months Crispr Therapeutics AG (CRSP) made 5.21%, while its related Sector, the SPDR S&P Biotech (XBI) made 7.17%.
Over the last 3 months CRSP made -13.36%, while XBI made 1.78%.
No, over the last 12 months Crispr Therapeutics AG (CRSP) made 5.21%, while its related Sector, the SPDR S&P Biotech (XBI) made 7.17%.
Over the last 3 months CRSP made -13.36%, while XBI made 1.78%.
| Period | CRSP | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -14.09% | 0.55% | -0.35% |
| 3 Months | -13.36% | 1.78% | 4.13% |
| 12 Months | 5.21% | 7.17% | 28.03% |